Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - Apellis Pharmaceuticals, Inc. reported a revenue of $178.49 million for the quarter ended June 2025, reflecting a year-over-year decline of 10.6% [1] - The earnings per share (EPS) for the same period was -$0.33, compared to -$0.28 a year ago, with a consensus EPS estimate of -$0.44, resulting in a surprise of +25% [1] Revenue Breakdown - Product revenue, net was $171.39 million, below the 10-analyst average estimate of $176.3 million, representing a year-over-year change of -4.3% [4] - Licensing and other revenue amounted to $7.11 million, significantly lower than the 10-analyst average estimate of $12.89 million, showing a year-over-year decline of 65.4% [4] - Product revenue from EMPAVELI was $20.8 million, compared to the seven-analyst average estimate of $21.74 million, indicating a year-over-year change of -15.1% [4] - Product revenue from SYFOVRE was $150.6 million, slightly below the seven-analyst average estimate of $153.77 million, with a year-over-year change of -2.6% [4] Stock Performance - Shares of Apellis Pharmaceuticals have returned +6.6% over the past month, outperforming the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]